306 related articles for article (PubMed ID: 19952801)
1. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey.
Morgensztern D; Ng SH; Gao F; Govindan R
J Thorac Oncol; 2010 Jan; 5(1):29-33. PubMed ID: 19952801
[TBL] [Abstract][Full Text] [Related]
2. Cancer Statistics, 2017.
Siegel RL; Miller KD; Jemal A
CA Cancer J Clin; 2017 Jan; 67(1):7-30. PubMed ID: 28055103
[TBL] [Abstract][Full Text] [Related]
3. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Kochenderfer JN; Dudley ME; Carpenter RO; Kassim SH; Rose JJ; Telford WG; Hakim FT; Halverson DC; Fowler DH; Hardy NM; Mato AR; Hickstein DD; Gea-Banacloche JC; Pavletic SZ; Sportes C; Maric I; Feldman SA; Hansen BG; Wilder JS; Blacklock-Schuver B; Jena B; Bishop MR; Gress RE; Rosenberg SA
Blood; 2013 Dec; 122(25):4129-39. PubMed ID: 24055823
[TBL] [Abstract][Full Text] [Related]
4. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Goldstraw P; Chansky K; Crowley J; Rami-Porta R; Asamura H; Eberhardt WE; Nicholson AG; Groome P; Mitchell A; Bolejack V; ;
J Thorac Oncol; 2016 Jan; 11(1):39-51. PubMed ID: 26762738
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of lung cancer management in South Western Sydney.
Kang S; Koh ES; Vinod SK; Jalaludin B
J Med Imaging Radiat Oncol; 2012 Apr; 56(2):235-41. PubMed ID: 22498199
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
8. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M; Inoue A; Kobayashi K; Sugawara S; Oizumi S; Isobe H; Gemma A; Harada M; Yoshizawa H; Kinoshita I; Fujita Y; Okinaga S; Hirano H; Yoshimori K; Harada T; Ogura T; Ando M; Miyazawa H; Tanaka T; Saijo Y; Hagiwara K; Morita S; Nukiwa T;
N Engl J Med; 2010 Jun; 362(25):2380-8. PubMed ID: 20573926
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.
de Castro J; Tagliaferri P; de Lima VCC; Ng S; Thomas M; Arunachalam A; Cao X; Kothari S; Burke T; Myeong H; Grattan A; Lee DH
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28748556
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer.
Taunk NK; Rimner A; Culligan M; Friedberg JS; Brahmer J; Chaft J
Transl Lung Cancer Res; 2017 Apr; 6(2):178-185. PubMed ID: 28529900
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
Lancet Oncol; 2011 Aug; 12(8):735-42. PubMed ID: 21783417
[TBL] [Abstract][Full Text] [Related]
13. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.
Remark R; Becker C; Gomez JE; Damotte D; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH; Powell CA; Altorki NK; Merad M; Gnjatic S
Am J Respir Crit Care Med; 2015 Feb; 191(4):377-90. PubMed ID: 25369536
[TBL] [Abstract][Full Text] [Related]
14. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N; Santana-Davila R; Molina JR
Mayo Clin Proc; 2019 Aug; 94(8):1623-1640. PubMed ID: 31378236
[TBL] [Abstract][Full Text] [Related]
15. Lung cancer: current therapies and new targeted treatments.
Hirsch FR; Scagliotti GV; Mulshine JL; Kwon R; Curran WJ; Wu YL; Paz-Ares L
Lancet; 2017 Jan; 389(10066):299-311. PubMed ID: 27574741
[TBL] [Abstract][Full Text] [Related]
16. The biology and management of non-small cell lung cancer.
Herbst RS; Morgensztern D; Boshoff C
Nature; 2018 Jan; 553(7689):446-454. PubMed ID: 29364287
[TBL] [Abstract][Full Text] [Related]
17. Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.
Chi A; Chen H; Wen S; Yan H; Liao Z
Radiother Oncol; 2017 Jun; 123(3):346-354. PubMed ID: 28545956
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Ferrara R; Auger N; Auclin E; Besse B
J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer and miRNAs: a possible remedy for anti-metastatic, therapeutic and diagnostic applications.
Hashemi ZS; Khalili S; Forouzandeh Moghadam M; Sadroddiny E
Expert Rev Respir Med; 2017 Feb; 11(2):147-157. PubMed ID: 28118799
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.
Kris MG; Gaspar LE; Chaft JE; Kennedy EB; Azzoli CG; Ellis PM; Lin SH; Pass HI; Seth R; Shepherd FA; Spigel DR; Strawn JR; Ung YC; Weyant M
J Clin Oncol; 2017 Sep; 35(25):2960-2974. PubMed ID: 28437162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
